Tumor Heterogeneity: From Single Cells to Clinical Impact
September 10-13, 2020
Sheraton Philadelphia Downtown
Nicholas E. Navin, The University of Texas MD Anderson Cancer Center, Houston, Texas
Kornelia Polyak, Dana-Farber Cancer Institute, Boston, Massachusetts
Alexander K. Shalek, Massachusetts Institute of Technology, Cambridge, Massachusetts
Charles Swanton, The Francis Crick Institute and UCL Cancer Institute, London, United Kingdom
Tumors are composed of heterogeneous populations of cells that possess distinct genetic, morphological, and phenotypic profiles, which in turn can impact tumor development, treatment response, and therapeutic resistance. Additionally, even tumors with similar profiles may react differently depending on their microenvironment. This conference will bring together the top basic, translational, and clinical researchers in the field of tumor heterogeneity. Presentations will feature the most recent research on basic biological mechanisms, new technological and computational developments, approaches to targeting and monitoring heterogeneity, and the implications of these findings for the clinical setting.
For information on tabletop exhibits, please contact firstname.lastname@example.org. Space is limited.